{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T08:41:20Z","timestamp":1794904880744,"version":"4.9.1"},"reference-count":27,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2019,5,22]],"date-time":"2019-05-22T00:00:00Z","timestamp":1558483200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["K23 CA204726"],"award-info":[{"award-number":["K23 CA204726"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["j. immunotherapy cancer"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s40425-019-0617-x","type":"journal-article","created":{"date-parts":[[2019,5,22]],"date-time":"2019-05-22T03:03:11Z","timestamp":1558494191000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":347,"title":["Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study"],"prefix":"10.1136","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6390-773X","authenticated-orcid":false,"given":"Douglas B.","family":"Johnson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Manouchehri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra M.","family":"Haugh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry T.","family":"Quach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin M.","family":"Balko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedicte","family":"Lebrun-Vignes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Mammen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javid J.","family":"Moslehi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joe-Elie","family":"Salem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2019,5,22]]},"reference":[{"key":"617_CR1","doi-asserted-by":"publisher","first-page":"2500","DOI":"10.1056\/NEJMc1713444","volume":"377","author":"M Yarchoan","year":"2017","unstructured":"Yarchoan M, Hopkins A, Jaffee EM. Tumor mutational burden and response rate to PD-1 inhibition. N Engl J Med. 2017;377:2500\u20131.","journal-title":"N Engl J Med"},{"key":"617_CR2","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1126\/science.aar4060","volume":"359","author":"A Ribas","year":"2018","unstructured":"Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018;359:1350\u20135.","journal-title":"Science"},{"key":"617_CR3","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","volume":"378","author":"MA Postow","year":"2018","unstructured":"Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378:158\u201368.","journal-title":"N Engl J Med"},{"key":"617_CR4","doi-asserted-by":"crossref","unstructured":"Johnson DB, Chandra S, Sosman JA. Immune checkpoint inhibitor toxicity in 2018. JAMA. 2018.","DOI":"10.1001\/jama.2018.13995"},{"key":"617_CR5","unstructured":"Wang DY, Salem JE, Cohen JV, et al. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol. 2018."},{"key":"617_CR6","doi-asserted-by":"publisher","first-page":"e122","DOI":"10.1200\/JCO.2013.51.1683","volume":"33","author":"DB Johnson","year":"2015","unstructured":"Johnson DB, Saranga-Perry V, Lavin PJ, et al. Myasthenia gravis induced by Ipilimumab in patients with metastatic melanoma. J Clin Oncol. 2015;33:e122\u20134.","journal-title":"J Clin Oncol"},{"key":"617_CR7","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1634\/theoncologist.2016-0487","volume":"22","author":"J Larkin","year":"2017","unstructured":"Larkin J, Chmielowski B, Lao CD, et al. Neurologic serious adverse events associated with Nivolumab plus Ipilimumab or Nivolumab alone in advanced melanoma, including a case series of encephalitis. Oncologist. 2017;22:709\u201318.","journal-title":"Oncologist"},{"key":"617_CR8","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1093\/annonc\/mdw558","volume":"28","author":"L Spain","year":"2017","unstructured":"Spain L, Walls G, Julve M, et al. Neurotoxicity from immune-checkpoint inhibition in the treatment of melanoma: a single Centre experience and review of the literature. Ann Oncol. 2017;28:377\u201385.","journal-title":"Ann Oncol"},{"key":"617_CR9","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s40425-018-0393-z","volume":"6","author":"CA Garcia","year":"2018","unstructured":"Garcia CA, El-Ali A, Rath TJ, et al. Neurologic immune-related adverse events associated with adjuvant ipilimumab: report of two cases. J Immunother Cancer. 2018;6:83.","journal-title":"J Immunother Cancer"},{"key":"617_CR10","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.ejca.2016.02.024","volume":"60","author":"L Zimmer","year":"2016","unstructured":"Zimmer L, Goldinger SM, Hofmann L, et al. Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy. Eur J Cancer. 2016;60:210\u201325.","journal-title":"Eur J Cancer"},{"key":"617_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejca.2016.12.001","volume":"73","author":"S Cuzzubbo","year":"2017","unstructured":"Cuzzubbo S, Javeri F, Tissier M, et al. Neurological adverse events associated with immune checkpoint inhibitors: review of the literature. Eur J Cancer. 2017;73:1\u20138.","journal-title":"Eur J Cancer"},{"key":"617_CR12","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/S0140-6736(18)30533-6","volume":"391","author":"JJ Moslehi","year":"2018","unstructured":"Moslehi JJ, Salem JE, Sosman JA, et al. Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. Lancet. 2018;391:933.","journal-title":"Lancet"},{"key":"617_CR13","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1161\/CIRCULATIONAHA.118.035898","volume":"138","author":"C Anquetil","year":"2018","unstructured":"Anquetil C, Salem JE, Lebrun-Vignes B, et al. Immune checkpoint inhibitor-associated myositis. Circulation. 2018;138:743\u20135.","journal-title":"Circulation"},{"key":"617_CR14","doi-asserted-by":"crossref","unstructured":"Wright JJ, Salem JE, Johnson DB, et al. Increased reporting of immune checkpoint inhibitor-associated diabetes. Diabetes Care. 2018.","DOI":"10.2337\/dc18-1465"},{"key":"617_CR15","doi-asserted-by":"crossref","unstructured":"Arnaud L, Lebrun-Vignes B, Salem JE. Checkpoint inhibitor-associated immune arthritis. Ann Rheum Dis. 2018.","DOI":"10.1136\/annrheumdis-2018-213470"},{"key":"617_CR16","doi-asserted-by":"crossref","unstructured":"Salem JE, Manouchehri A, Moey M, et al. Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. Lancet Oncol. 2018.","DOI":"10.1016\/S1470-2045(18)30608-9"},{"key":"617_CR17","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1177\/009286150804200501","volume":"42","author":"M Lindquist","year":"2008","unstructured":"Lindquist M. VigiBase, the WHO global ICSR database system: basic facts. Drug Inf J. 2008;42:409\u201319.","journal-title":"Drug Inf J"},{"key":"617_CR18","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s002280050466","volume":"54","author":"A Bate","year":"1998","unstructured":"Bate A, Lindquist M, Edwards IR, et al. A Bayesian neural network method for adverse drug reaction signal generation. Eur J Clin Pharmacol. 1998;54:315\u201321.","journal-title":"Eur J Clin Pharmacol"},{"key":"617_CR19","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1177\/0962280211403604","volume":"22","author":"GN Noren","year":"2013","unstructured":"Noren GN, Hopstadius J, Bate A. Shrinkage observed-to-expected ratios for robust and transparent large-scale pattern discovery. Stat Methods Med Res. 2013;22:57\u201369.","journal-title":"Stat Methods Med Res"},{"key":"617_CR20","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1093\/eurheartj\/ehi092","volume":"26","author":"ML Bruin De","year":"2005","unstructured":"De Bruin ML, Pettersson M, Meyboom RH, et al. Anti-HERG activity and the risk of drug-induced arrhythmias and sudden death. Eur Heart J. 2005;26:590\u20137.","journal-title":"Eur Heart J"},{"key":"617_CR21","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/pds.1001","volume":"13","author":"KJ Rothman","year":"2004","unstructured":"Rothman KJ, Lanes S, Sacks ST. The reporting odds ratio and its advantages over the proportional reporting ratio. Pharmacoepidemiol Drug Saf. 2004;13:519\u201323.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"617_CR22","doi-asserted-by":"crossref","unstructured":"Grouthier V, Lebrun-Vignes B, Glazer AM, et al. Increased long QT and torsade de pointes reporting on tamoxifen compared with aromatase inhibitors. Heart. 2018.","DOI":"10.1136\/heartjnl-2017-312934"},{"key":"617_CR23","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1172\/JCI58649","volume":"122","author":"A Nylander","year":"2012","unstructured":"Nylander A, Hafler DA. Multiple sclerosis. J Clin Invest. 2012;122:1180\u20138.","journal-title":"J Clin Invest"},{"key":"617_CR24","doi-asserted-by":"crossref","unstructured":"McCauley ME, Baloh RH. Inflammation in ALS\/FTD pathogenesis. Acta Neuropathol. 2018.","DOI":"10.1007\/s00401-018-1933-9"},{"key":"617_CR25","doi-asserted-by":"publisher","first-page":"312","DOI":"10.3389\/fnagi.2018.00312","volume":"10","author":"A Mishra","year":"2018","unstructured":"Mishra A, Brinton RD. Inflammation: bridging age, menopause and APOEepsilon4 genotype to Alzheimer's disease. Front Aging Neurosci. 2018;10:312.","journal-title":"Front Aging Neurosci"},{"key":"617_CR26","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/s41582-018-0028-5","volume":"14","author":"X Hu","year":"2018","unstructured":"Hu X, Leak RK, Thomson AW, et al. Promises and limitations of immune cell-based therapies in neurological disorders. Nat Rev Neurol. 2018;14:559\u201368.","journal-title":"Nat Rev Neurol"},{"key":"617_CR27","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","volume":"375","author":"DB Johnson","year":"2016","unstructured":"Johnson DB, Balko JM, Compton ML, et al. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med. 2016;375:1749\u201355.","journal-title":"N Engl J Med"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-019-0617-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s40425-019-0617-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-019-0617-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,13]],"date-time":"2020-12-13T20:03:50Z","timestamp":1607889830000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1186\/s40425-019-0617-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,22]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["617"],"URL":"https:\/\/doi.org\/10.1186\/s40425-019-0617-x","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,22]]},"assertion":[{"value":"11 March 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 information"}},{"value":"All clinical data was de-identified and in a publicly available database (Vigibase).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"DBJ serves on advisory boards for Array Biopharma, BMS, Genoptix, Incyte, and Merck, and receives research funding from BMS and Incyte. JJM serves on advisory boards for Pfizer, Novartis, BMS, Takeda, Myokardia, Regeneron, and Decipher, and receives research funding from BMS and Pfizer.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"134"}}